Transforming Growth Factor beta-1
Swiss-Prot Accession Number: P01137
Swiss-Prot Accession Number: P01137
Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma. (2020) Wick A, Desjardins A, Suarez C, Forsyth P, Gueorguieva I, Burkholder T, Cleverly AL, Estrem ST, Wang S, Lahn MM, Guba SC, Capper D, Rodon J Investigational New Drugs
medical_services Therapy IndicationsDegree of Genetic Liability for Alzheimer?s Disease Associated with Specific Proteomic Profiles in Cerebrospinal Fluid (2020) Reus LM, Stringer S, Posthuma D, Teunissen CE, Scheltens P, Pijnenburg YAL, Visser PJ, Tijms BM, for the Alzheimers Disease Neuroimaging Neurology of Aging
medical_services Therapy Indications
A leading global drug discovery and development laboratory, IQVIA Laboratories (the laboratory business of IQVIA) provides customers with a comprehensive assemblage of solutions encompassing central laboratory and specialty biomarker services including genomics, immunoassays, flow cytometry, anatomic pathology, precision medicine assays, vaccine assays, ADME and bioanalytical along with extensive offerings in antibody drug discovery, biomarker discovery, and decentralized clinical trial lab solutions.
Learn more at labs.iqvia.com
Copyright 2026 Rules-Based Medicine. All rights reserved. RBM does not sell your personal information.